Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSA006 in Chinese Patients With NASH
NCT06322628Phase 2Active, not recruiting
- Sponsor
- Visirna Therapeutics
- Start
- Apr 2024
- Primary completion
- Jul 2026
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of gatuzosiran in Nonalcoholic steatohepatitis (NASH), sponsored by Visirna Therapeutics. Started Apr 2024; status: active, not recruiting.
02
Drugs
gatuzosiran
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06322628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322628.